Home Industries Reports Services About Us Publisher Contact us

Global Immunotherapy Drugs Market By Type (Monoclonal Antibodies, Check Point Inhibitors, Interferons, and Interleukins), Therapy Area (Cancer, Autoimmune diseases& Inflammatory, Infectious Diseases), End-User (Hospitals, Clinics), By Region, Industry Analysis, Share, Growth, Trends, and Forecast, 2021-2028

Covid-19 Impact on Global Immunotherapy Drugs Market

Type: PDF

Status: Published

Categories: Pharma & Healthcare

Report Code : PHC214032

No. of Pages : 317

The global immunotherapy drugs market is expected to grow from USD 163.2 billion in 2020 to USD 381.5 billion by 2028 at a CAGR of 11.2 % over the forecast period 2021-2028.


Market Overview:


Immunotherapy drug is biologic therapy, which is a sort of cancer treatment. This treatment enhances the body's natural immunity to fight cancer. It utilizes biological substances to enhance system function by stopping cancer cells' expansion and helping the system figure better at destroying cancer cells. There are various types of immunotherapy available such as oncolytic virus therapy, monoclonal antibodies, non-specific immunotherapies, T-cell therapy, and cancer vaccines.


The global immunotherapy drug market is expected to grow due to driving factors like the rising prevalence of cancer worldwide and advancement within development techniques.


Market Dynamics:


Drivers:



  • Increasing cases of target diseases

  • Growing demand for immunotherapy drugs over conventional treatments


Restraints:



  • Issues related to side-effects and manufacturing complexities

  • High friction rate in the product development cycle


Key Market Players:


Eli Lilly and Company, AstraZeneca, Abbvie, Amgen Inc, GlaxoSmithKline Plc, Novartis International AG, Merck, F. Hoffmann-La Roche AG, Bristol-Myers Squibb, UbiVac are some of the prominent players in the global immunotherapy drugs market.


The market is segmented based on the below-mentioned segments:


On the Basis of Type: Revenue & Volume


o   Monoclonal Antibodies


o   Check Point Inhibitors


o   Interferons


o   Interleukins


On the Basis of Therapy Area: Revenue & Volume


o   Cancer


o   Autoimmune diseases & Inflammatory


o   Infectious Diseases


On the Basis of End-User: Revenue & Volume


o   Hospitals


o   Clinics


On The Basis of Region: Revenue & Volume



  • North America





    • U.S.A

    • Canada

    • Mexico





  • Europe





    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Rest of Europe





  • Asia Pacific





    • China

    • Japan

    • India

    • SEA

    • Australia

    • Rest Of APAC





  • South America





    • Brazil

    • Argentina

    • Rest of South America





  • Middle East & Africa





    • South Africa

    • Saudi Arabia

    • UAE

    • Rest of MEA




Report Description



  • Year Consideration

    • Base year – 2020

    • Historic Year-2017-2019

    • Forecast year- 2021 to 2028



  • The global immunotherapy drugs market will be based on revenue and volume. The study covers the market share for segments, countries, regions, and players.

  • The regions evaluated for the global immunotherapy drugs market are Europe, North America, Asia Pacific, South America, and Middle East & Africa. Furthermore, the regions are further analyzed at the country-level.

  • The report provides an in-depth pricing analysis, value chain analysis, industry road map, and micro and macro factors.

  • The research report further provides the attractiveness of immunotherapy drugs and regions based on their growth rate (CAGR), market size, and attractiveness by analyzing present and future prospects to analyze market growth and development in the future.

  • Also, the study focuses on market-related driving forces, restraints, potential opportunities for the market, significant developments, and advancement that serve as a key potential for investors.

  • The study offers an extensive evaluation of Porter's five forces analysis, SWOT analysis, and PESTEL analysis to provide data and information related to the business.

  • Porter's five forces model is analyzed to understand the overall competitive scenario that prevails in the market. The SWOT analysis also identifies the positive as well as the negative characteristics of market development which influences the company’s growth and development to sustain and survive in the long run. The PESTEL analysis identifies the macro (external) forces affecting the organization.

  • The report includes a thorough analysis of the company profiles of major companies operating in the global immunotherapy drugs market and a comparative evaluation based on their business overviews, product offering, geographic presence, market share, business strategy, recent developments, product development & innovations, joint ventures, partnerships, mergers & acquisitions, expansions, SWOT analysis, and key financial information. It helps in evaluating the overall competition present in the market scenario.

Request For Request Sample

To receive a sample copy of this report, please complete the form below

Kindly share your specific requirement (if any), so we can get back to you with a solution

TABLE OF CONTENTS
1.    INTRODUCTION 
1.1. OBJECTIVES OF THE STUDY 
1.2. SCOPE OF THE STUDY
1.3. GEOGRAPHIC SCOPE 
1.4. MARKET DEFINITION 
1.5. CURRENCY CONSIDERATION 
1.6. YEAR CONSIDERATION 
2.    RESEARCH METHODOLOGY AND ASSUMPTIONS
2.1. SECONDARY RESEARCH
2.2. PRIMARY RESEARCH 
2.3. MARKET BREAKUP AND DATA TRIANGULATION
2.4. MARKET SIZE ESTIMATION
2.4.1. BOTTOM UP APPROACH
2.4.2. TOP DOWN APPROACH
2.5. ASSUMPTION 
3.    EXECUTIVE SUMMARY
3.1. KEY MARKET INSIGHTS 
3.2. SEGMENTATION OUTLOOK
3.3. COMPANY OUTLOOK
4.    PREMIUM INSIGHTS
4.1. IMPACT OF COVID-19 ON MARKET
4.2. INDUSTRY ROAD MAP
4.3. INDUSTRY TREND
4.4. INDUSTRY SWOT ANALYSIS 
4.5. MARKET ATTRACTIVENESS ANALYSIS 
4.5.1. MARKET ATTRACTIVENESS BY SEGMENTS 
4.5.1.1. IMMUNOTHERAPY DRUGS MARKET ATTENTIVENESS BY TYPE
4.5.1.2. IMMUNOTHERAPY DRUGS MARKET ATTENTIVENESS BY THERAPY AREA
4.5.1.3. IMMUNOTHERAPY DRUGS MARKET ATTENTIVENESS BY END-USER
4.5.2. MARKET ATTRACTIVENESS BY REGION 
4.5.2.1.   NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET ATTENTIVENESS BY COUNTRY
4.5.2.2. EUROPE IMMUNOTHERAPY DRUGS MARKET ATTENTIVENESS BY COUNTRY
4.5.2.3. ASIA PACIFIC IMMUNOTHERAPY DRUGS MARKET ATTENTIVENESS BY COUNTRY
4.5.2.4. SOUTH AMERICA IMMUNOTHERAPY DRUGS MARKET ATTENTIVENESS BY COUNTRY
4.5.2.5. MIDDLE EAST AND AFRICA IMMUNOTHERAPY DRUGS MARKET ATTENTIVENESS BY COUNTRY
4.6. PORTER’S FIVE FORCES ANALYSIS 
4.6.1. THREAT OF NEW ENTRANTS
4.6.2. THREAT OF SUBSTITUTES
4.6.3. BARGAINING POWER OF SUPPLIERS
4.6.4. BARGAINING POWER OF BUYERS
4.6.5. INTENSITY OF COMPETITIVE RIVALRY
4.7. VALUE CHAIN ANALYSIS 
4.7.1. RESEARCH & DEVELOPMENT COMPANIES
4.7.2. RAW MATERIAL/ COMPONENT SUPPLIERS
4.7.3.  PRODUCT MANUFACTURERS
4.7.4. DISTRIBUTORS AND RETAILERS
4.7.5. END-USER INDUSTRIES
4.7.6. POST-SALES SERVICE PROVIDERS
4.8. FACTORS AFFECTING THE MARKET
4.8.1. MACRO FACTORS AFFECTING THE MARKET
4.8.2. MICRO FACTORS AFFECTING THE MARKET
4.8.3. PESTEL ANALYSIS 
4.9. YEAR ON YEAR GROWTH RATE OF IMMUNOTHERAPY DRUGS 
4.10. LIST OF SUPPLIERS 
4.11. LIST OF BUYERS 
4.12. COUNTRY LEVEL ANALYSIS 
4.13. RULES AND REGULATION 
5.    MARKET DYNAMICS
5.1. MARKET DRIVERS
5.1.1. INCREASING CASES OF TARGET DISEASES
5.1.2. GROWING DEMAND FOR IMMUNOTHERAPY DRUGS OVER CONVENTIONAL TREATMENTS
5.2. MARKET RESTRAINTS
5.2.1. ISSUES RELATED TO SIDE-EFFECTS AND MANUFACTURING COMPLEXITIES
5.2.2. HIGH FRICTION RATE IN THE PRODUCT DEVELOPMENT CYCLE
5.3. MARKET OPPORTUNITIES
5.4. MARKET CHALLENGES
6.    GLOBAL IMMUNOTHERAPY DRUGS MARKET INSIGHTS AND FORECAST ANALYSIS, BY TYPE - 2017-2028
6.1. KEY FINDINGS 
6.2. MONOCLONAL ANTIBODIES
6.3. CHECK POINT INHIBITORS
6.4. INTERFERONS
6.5. INTERLEUKINS
7.    GLOBAL IMMUNOTHERAPY DRUGS MARKET INSIGHTS AND FORECAST ANALYSIS, BY THERAPY AREA - 2017-2028
7.1. KEY FINDINGS 
7.2. CANCER
7.3. AUTOIMMUNE DISEASES & INFLAMMATORY
7.4. INFECTIOUS DISEASES
8.    GLOBAL IMMUNOTHERAPY DRUGS MARKET INSIGHTS AND FORECAST ANALYSIS, BY END-USER - 2017-2028
8.1. KEY FINDINGS 
8.2. HOSPITALS
8.3. CLINICS
9.    GLOBAL IMMUNOTHERAPY DRUGS MARKET INSIGHTS AND FORECAST ANALYSIS, BY REGIONAL - 2017-2028
9.1. KEY FINDINGS 
9.2. NORTH AMERICA
9.3. EUROPE
9.4. ASIA PACIFIC
9.5. SOUTH AMERICA
9.6. MIDDLE EAST & AFRICA
10.    NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET INSIGHTS AND FORECAST ANALYSIS, BY SEGMENTS AND COUNTRY - 2017-2028
10.1. BY COUNTRY 
10.1.1. U.S.
10.1.2. CANADA
10.1.3. MEXICO
11.    EUROPE IMMUNOTHERAPY DRUGS MARKET INSIGHTS AND FORECAST ANALYSIS, BY SEGMENTS AND COUNTRY - 2017-2028
11.1. BY COUNTRY 
11.1.1. GERMANY
11.1.2. U.K.
11.1.3. FRANCE
11.1.4. ITALY
11.1.5. SPAIN
11.1.6. SWEDEN
11.1.7. BELGIUM
11.1.8. TURKEY
11.1.9. RUSSIA
11.1.10. POLAND
11.1.11. SWITZERLAND
11.1.12. NETHERLANDS
11.1.13. REST OF EUROPE
12.    ASIA PACIFIC IMMUNOTHERAPY DRUGS MARKET INSIGHTS AND FORECAST ANALYSIS, BY SEGMENTS AND COUNTRY - 2017-2028
12.1. BY COUNTRY 
12.1.1.1. JAPAN
12.1.1.2. CHINA
12.1.1.3. INDIA
12.1.1.4. AUSTRALIA
12.1.1.5. SOUTH KOREA
12.1.1.6. MALAYSIA
12.1.1.7. INDONESIA 
12.1.1.8. VIETNAM
12.1.1.9. NEW ZEALAND
12.1.1.10. PHILIPPINES
12.1.1.11. TAIWAN
12.1.1.12. SINGAPORE
12.1.1.13. REST OF ASIA-PACIFIC
13.    SOUTH AMERICA IMMUNOTHERAPY DRUGS MARKET INSIGHTS AND FORECAST ANALYSIS, BY SEGMENTS AND COUNTRY - 2017-2028
13.1. BY COUNTRY 
13.1.1.1. BRAZIL
13.1.1.2. ARGENTINA
13.1.1.3. CHILE
13.1.1.4. COLOMBIA
13.1.1.5. REST OF SOUTH AMERICA
14.    MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET INSIGHTS AND FORECAST ANALYSIS, BY SEGMENTS AND COUNTRY - 2017-2028
14.1. BY COUNTRY 
14.1.1.1. SOUTH AFRICA
14.1.1.2. U.A.E.
14.1.1.3. SAUDI ARABIA
14.1.1.4. REST OF MIDDLE EAST AND AFRICA
15.    COMPETITIVE LANDSCAPE
15.1. MARKET SHARE OF KEY PLAYERS IN POWER TOOL MARKET
15.1.1. GLOBAL MARKET SHARE ANALYSIS 
15.1.2. NORTH AMERICA MARKET SHARE ANALYSIS 
15.1.3. EUROPE MARKET SHARE ANALYSIS 
15.1.4. ASIA PACIFIC MARKET SHARE ANALYSIS 
15.1.5. SOUTH AMERICA MARKET SHARE ANALYSIS
15.1.6. MIDDLE EAST & AFRICA MARKET SHARE ANALYSIS
15.2. LEADERSHIP MAPPING
15.2.1. VISIONARY PLAYERS
15.2.2. INNOVATORS PLAYERS
15.2.3. DYNAMIC DIFFERENTIATORS
15.2.4. EMERGING COMPANIES
15.3. COMPETITIVE SCENARIO AND TRENDS
15.3.1. MERGERS & ACQUISITIONS
15.3.2. PRODUCT LAUNCHES AND DEVELOPMENTS
15.3.3. PARTNERSHIPS, COLLABORATIONS, AND AGREEMENTS
15.3.4. EXPANSIONS
16.    COMPANY PROFILES
16.1.1. ELI LILLY AND COMPANY
16.1.1.1. COMPANY OVERVIEW
16.1.1.2. COMPANY SNAPSHOT
16.1.1.3. FINANCIAL ANALYSIS
16.1.1.3.1.       REVENUE ANALYSIS 
16.1.1.3.2.    SALES ANALYSIS 
16.1.1.3.3.    PRICE ANALYSIS
16.1.1.3.4.    MARGIN ANALYSIS 
16.1.1.4. GEOGRAPHICAL PRESENCE
16.1.1.4.1.       NORTH AMERICA
16.1.1.4.2.    EUROPE
16.1.1.4.3.    ASIA PACIFIC
16.1.1.4.4.    SOUTH AMERICA
16.1.1.4.5.    MIDDLE EAST & AFRICA
16.1.1.5. PRODUCT PORTFOLIO
16.1.1.6. SWOT ANALYSIS
16.1.1.7. RECENT DEVELOPMENT
16.1.2. ASTRAZENECA
16.1.3. ABBVIE
16.1.4. AMGEN INC
16.1.5. GLAXOSMITHKLINE PLC
16.1.6. NOVARTIS INTERNATIONAL AG
16.1.7. MERCK
16.1.8. F. HOFFMANN-LA ROCHE AG
16.1.9. BRISTOL-MYERS SQUIBB
16.1.10. UBIVAC
17.    STRATEGIC RECOMMENDATIONS
LIST OF TABLE    
1.    RESEARCH ASSUMPTION 
2.    COVID-19 IMPACT ON MARKET
3.    MAJOR DEVELOPMENTS BY VARIOUS COMPANIES
4.    GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION) 
5.    GLOBAL MONOCLONAL ANTIBODIES IMMUNOTHERAPY DRUGS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
6.    GLOBAL CHECK POINT INHIBITORS IMMUNOTHERAPY DRUGS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
7.    GLOBAL INTERFERONS IMMUNOTHERAPY DRUGS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
8.    GLOBAL INTERLEUKINS IMMUNOTHERAPY DRUGS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
9.    GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
10.    GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
11.    GLOBAL AUTOIMMUNE DISEASES & INFLAMMATORY IMMUNOTHERAPY DRUGS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
12.    GLOBAL INFECTIOUS DISEASES IMMUNOTHERAPY DRUGS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
13.    GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
14.    GLOBAL HOSPITALS IMMUNOTHERAPY DRUGS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
15.    GLOBAL CLINICS IMMUNOTHERAPY DRUGS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION) 
16.    GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY NORTH AMERICA, 2017–2028 REVENUE (USD MILLION)
17.    NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
18.    NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
19.    NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
20.    U.S. IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
21.    U.S. IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
22.    U.S. IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
23.    CANADA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
24.    CANADA IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
25.    CANADA IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
26.    MEXICO IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
27.    MEXICO IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
28.    MEXICO IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
29.    EUROPE IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
30.    EUROPE IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
31.    EUROPE IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
32.    GERMANY IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
33.    GERMANY IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
34.    GERMANY IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
35.    FRANCE IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
36.    FRANCE IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
37.    FRANCE IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
38.    U.K. IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
39.    U.K. IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
40.    U.K. IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
41.    ITALY IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
42.    ITALY IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
43.    ITALY IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
44.    SPAIN IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
45.    SPAIN IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
46.    SPAIN IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
47.    SWEDEN IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
48.    SWEDEN IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
49.    SWEDEN IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
50.    BELGIUM IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
51.    BELGIUM IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
52.    BELGIUM IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
53.    TURKEY IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
54.    TURKEY IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
55.    TURKEY IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
56.    RUSSIA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
57.    RUSSIA IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
58.    RUSSIA IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
59.    POLAND IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
60.    POLAND IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
61.    POLAND IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
62.    SWITZERLAND IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
63.    SWITZERLAND IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
64.    SWITZERLAND IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
65.    NETHERLANDS IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
66.    NETHERLANDS IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
67.    NETHERLANDS IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
68.    ASIA PACIFIC IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
69.    ASIA PACIFIC IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
70.    ASIA PACIFIC IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
71.    JAPAN IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
72.    JAPAN IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
73.    JAPAN IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
74.    CHINA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
75.    CHINA IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
76.    CHINA IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
77.    INDIA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
78.    INDIA IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
79.    INDIA IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
80.    AUSTRALIA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
81.    AUSTRALIA IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
82.    AUSTRALIA IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
83.    SOUTH KOREA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
84.    SOUTH KOREA IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
85.    SOUTH KOREA IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
86.    INDONESIA  IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
87.    INDONESIA  IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
88.    INDONESIA IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
89.    VIETNAM IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
90.    VIETNAM IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
91.    VIETNAM IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
92.    NEW ZEALAND IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
93.    NEW ZEALAND IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
94.    NEW ZEALAND  IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
95.    PHILIPPINES IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
96.    PHILIPPINES IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
97.    PHILIPPINES IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
98.    TAIWAN IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
99.    TAIWAN IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
100.    TAIWAN IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
101.    SINGAPORE IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
102.    SINGAPORE IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
103.    SINGAPORE IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
104.    SOUTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
105.    SOUTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
106.    SOUTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
107.    BRAZIL IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
108.    BRAZIL IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
109.    BRAZIL IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
110.    ARGENTINA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
111.    ARGENTINA IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
112.    ARGENTINA IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
113.    CHILE IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
114.    CHILE IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
115.    CHILE IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
116.    COLOMBIA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
117.    COLOMBIA IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
118.    COLOMBIA IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
119.    MIDDLE EAST AND AFRICA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
120.    MIDDLE EAST AND AFRICA IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
121.    MIDDLE EAST AND AFRICA IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
122.    UAE IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
123.    UAE IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
124.    UAE IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
125.    SOUTH AFRICA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
126.    SOUTH AFRICA IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
127.    SOUTH AFRICA IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
128.    SAUDI ARABIA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
129.    SAUDI ARABIA IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
130.    SAUDI ARABIA IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
131.    REST OF MEA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
132.    REST OF MEA IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
133.    REST OF MEA IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)


LIST OF FIGURE
1.    RESEARCH DESIGN
2.    SCOPE OF THE STUDY
3.    GEOGRAPHIC SCOPE 
4.    CURRENCY CONSIDERATION 
5.    YEAR CONSIDERATION 
6.    MARKET ESTIMATION
7.    RESEARCH METHODOLOGY
8.    DATA TRIANGULATION
9.    COVID-19 IMPACT ON MARKET
10.    GLOBAL IMMUNOTHERAPY DRUGS  MARKET ATTRACTIVENESS ANALYSIS BY TYPE
11.    GLOBAL IMMUNOTHERAPY DRUGS  MARKET ATTRACTIVENESS ANALYSIS BY THERAPY AREA 
12.    GLOBAL IMMUNOTHERAPY DRUGS  MARKET ATTRACTIVENESS ANALYSIS BY END-USER
13.    GLOBAL IMMUNOTHERAPY DRUGS  MARKET ATTRACTIVENESS ANALYSIS BY REGION
14.    GLOBAL IMMUNOTHERAPY DRUGS  MARKET ATTRACTIVENESS ANALYSIS BY COUNTRY
15.    GLOBAL IMMUNOTHERAPY DRUGS  MARKET: DYNAMICS
16.    PESTEL ANALYSIS
17.    SWOT ANALYSIS 
18.    GLOBAL IMMUNOTHERAPY DRUGS MARKET ANALYSIS BY REGION
19.    GLOBAL IMMUNOTHERAPY DRUGS MARKET ANALYSIS BY TYPE
20.    GLOBAL IMMUNOTHERAPY DRUGS MARKET ANALYSIS BY THERAPY AREA
21.    GLOBAL IMMUNOTHERAPY DRUGS MARKET ANALYSIS BY END-USER
22.    GLOBAL IMMUNOTHERAPY DRUGS MARKET ANALYSIS BY NORTH AMERICA
23.    GLOBAL IMMUNOTHERAPY DRUGS MARKET ANALYSIS BY EUROPE
24.    GLOBAL IMMUNOTHERAPY DRUGS MARKET ANALYSIS BY ASIA PACIFIC
25.    GLOBAL IMMUNOTHERAPY DRUGS MARKET ANALYSIS BY SOUTH AMERICA
26.    GLOBAL IMMUNOTHERAPY DRUGS MARKET ANALYSIS BY MIDDLE EAST & AFRICA
27.    GLOBAL IMMUNOTHERAPY DRUGS MARKET SHARE BY COMPANY (2020)
28.    NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET SHARE BY COMPANY (2020)
29.    EUROPE IMMUNOTHERAPY DRUGS MARKET SHARE BY COMPANY (2020)
30.    ASIA PACIFIC IMMUNOTHERAPY DRUGS MARKET SHARE BY COMPANY (2020)
31.    SOUTH AMERICA IMMUNOTHERAPY DRUGS MARKET SHARE BY COMPANY (2020)
32.    MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SHARE BY COMPANY (2020)


 

Request For Research Methodology

To receive a sample copy of this report, please complete the form below

Kindly share your specific requirement (if any), so we can get back to you with a solution
Zenith Market Insights

Report Code

PHC214032

Single User

US$ 3500

Multi User

US$ 5250

Corporate User

US$ 7000

Global Immunotherapy Drugs Market By Type (Monoclo...

RD Code : PHC214032